Thomas C Hanff
Overview
Explore the profile of Thomas C Hanff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
824
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Peters C, Hanff T, Genuardi M, Zhang R, Domenico C, Atluri P, et al.
J Clin Med
. 2022 Jul;
11(13).
PMID: 35807184
Aims: While it is common practice to use intravenous (IV) iron in patients with left ventricular assist devices (LVADs) and iron deficiency, there is insufficient evidence regarding outcomes in this...
32.
Siripanthong B, Asatryan B, Hanff T, Chatha S, Khanji M, Ricci F, et al.
JACC Basic Transl Sci
. 2022 Feb;
7(3):294-308.
PMID: 35165665
The mechanisms of coronavirus disease-2019 (COVID-19)-related myocardial injury comprise both direct viral invasion and indirect (hypercoagulability and immune-mediated) cellular injuries. Some patients with COVID-19 cardiac involvement have poor clinical outcomes,...
33.
Edelson J, Edwards J, Katcoff H, Mondal A, Chen F, Reza N, et al.
J Am Heart Assoc
. 2022 Jan;
11(2):e020942.
PMID: 35023355
Background The past decade has seen tremendous growth in patients with ambulatory ventricular assist devices. We sought to identify patients that present to the emergency department (ED) at the highest...
34.
35.
Zhang R, Hanff T, Peters C, Evans P, Marble J, Rame J, et al.
ASAIO J
. 2021 Sep;
68(6):822-828.
PMID: 34560718
Continuous-flow left ventricular assist devices (CF-LVAD) have been shown to enhance reverse remodeling and myocardial recovery in certain patients allowing for device removal. We sought to analyze the characteristics and...
36.
Genuardi M, Moss N, Najjar S, Houston B, Shore S, Vorovich E, et al.
J Heart Lung Transplant
. 2021 Jun;
40(9):926-935.
PMID: 34140222
Background: COVID-19 continues to inflict significant morbidity and mortality, particularly on patients with preexisting health conditions. The clinical course, outcomes, and significance of immunosuppression regimen in heart transplant recipients with...
37.
Edwards J, Edelson J, Katcoff H, Mondal A, Lefkowitz D, Reza N, et al.
Am Heart J
. 2021 Jun;
240:11-15.
PMID: 34089695
There are limited data describing the prevalence of mental health disorders (MHDOs) in patients with ventricular assist devices (VADs), or associations between MHDOs and resource use or outcomes. We used...
38.
Khatana S, Hanff T, Nathan A, Dayoub E, Grandin E, Rame J, et al.
Circ Heart Fail
. 2021 May;
14(5):e008277.
PMID: 33993721
Background: Due to the high cost of left ventricular assist device (LVAD) therapy, payer type may be an important factor in determining eligibility. How payer type influences outcomes after LVAD...
39.
Zamani P, Proto E, Wilson N, Fazelinia H, Ding H, Spruce L, et al.
ESC Heart Fail
. 2021 May;
8(4):2698-2712.
PMID: 33991175
Aims: Skeletal muscle (SkM) abnormalities may impact exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF). We sought to quantify differences in SkM oxidative phosphorylation capacity (OxPhos),...
40.
Derington C, Cohen J, Mohanty A, Greene T, Cook J, Ying J, et al.
PLoS One
. 2021 Apr;
16(4):e0248080.
PMID: 33891615
Background: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) may positively or negatively impact outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We investigated the association...